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1. Introduction 
Specific antibody deficiency (SAD) is a common antibody immunodeficiency defined as a 
poor antibody response to unconjugated pneumococcal polysccharides present in the 23-
valent pneumococcal vaccine (PPV23). Clinical manifestations of specific antibody 
deficiency include recurrent sinopulmonary infections, such as sinusitis, otitis media, 
bronchitis, and pneumonia. All immunoglobulin concentrations, including IgG subclasses, 
are normal, and antibody response to protein antigens (eg, tetanus toxoid, diphtheria 
toxoid) and the conjugate H influenzae b vaccine are also normal in most patients. [11, 44, 56] In 
some patients with SAD, the response to the pneumococcal conjugate vaccines (PCV7, 
PCV10, and PCV13) is also normal. 
SAD was first reported in a small group of patients in the early 1980s. [6, 46] The widespread 
use of pneumococcal immunization to assess antibody responses has revealed that specific 
unresponsiveness to polysaccharide antigens is not unusual. [21, 25] 
The vast majority of SAD patients have a deficiency of specific antibodies to polysaccharides 
but normal antibodies to protein antigens, resembling the developing immunologic status of 
human newborns and infants. Infants readily produce antibodies against vaccine proteins 
but fail to respond to most vaccine polysaccharides until approximately two years of age. In 
some patient with early onset SAD, this condition may represent a delayed maturation of 
the immune response to polysaccharides.  
SAD is also found in association with many primary and secondary immunodeficiencies. An 
association of SAD with IgG subclass deficiencies, particulary IgG2 deficiencies, has been 
described. [9] IgG2 subclass deficient patients have antibody responses to a restricted number 
of polysaccharides in the PPV vaccine. Frequently, these patients also have poor 
immunological memory, with IgG antibody titers decreasing to pre-immunization levels 
within 6 to 12 months. [51] 
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Other primary immunodeficiency disorders with an immunologic phenotype associated 
with specific antibody deficiency include Wiskott-Aldrich syndrome, partial DiGeorge 
syndrome, asplenia, hyper-IgE syndrome, and selective IgA deficiency (without IgG 
subclass deficiency). [30] In addition, specific antibody deficiency can be identified in some 
patients with congenital dysmorphic syndromes or chromosomal abnormalities associated 
with recurrent sinopulmonary infections. Acquired or secondary immunodeficiencies 
associated with specific antibody deficiency include splenectomy, immunosuppression, 
chronic lung disease, protein-calorie malnutrition, and human immunodeficiency virus 
infection. 
There is not a single pathogenic mechanism for specific anti-polysaccharide antibody 
deficiencies. The variable conditions in which an inability to respond to polysaccharides is 
found suggest that many different immunologic phenotypes may lead to the same clinical 
phenotypic antibody deficiency. Further defining different SAD phenotypes and relating 
these phenotypes to associated conditions may shed further insight into possible pathogenic 
mechanisms.  
2. Assessment of specific antibodies  
The assessment of specific antibodies always needs to take into account:  
1. Evidence of exposure to vaccines or infections. In the case of vaccines, this includes an 
exact record of immunizations;  
2. Time since last exposure or vaccination to the time of obtaining the blood sample to be 
tested ;  
3. Method of antibody measurement, including the method, the antigen used, the 
standards used to normalize values and normal values for different age groups 
obtained with the same method used to test the patient sample.  
All this information is essential to determine if the antibody response is normal or abnormal 
and also to determine if further immunization is likely to increase antibody titers and 
protection. 
Pneumococcal vaccines are an ideal tool to evaluate the ability to produce specific 
antibodies in response to a known stimulus. All pneumococcal vaccines contain antigens 
from several serotypes so the immunologic evaluation is not based on a single antibody 
response. More recently, research has also revealed that these serotypes allow for clear 
differentiation between antibody responses to conjugate and pure polysaccharide vaccines, 
a difference that is clinically relevant.  
Current recommendations for the use of pneumococcal vaccines are based on the age at 
which immunization began. Pneumococcal conjugate vaccines (PCV) are recommended for 
all infants at 2, 4, 6 and 12 months of age. PCV has also been used in children 24 to 59 
months of age who are unimmunized, had incomplete vaccination prior to age 24 months, 
or are at high risk of acquired invasive pneumococcal disease [2].  
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The pneumococcal polysaccharide vaccine (PPV23) is not recommended for children under 
24 months since the responses to polysaccharide antigens is considered absent or ineffective 
in the first 2 years of life. Pneumococcal polysaccharide vaccines (PPV23) are recommended 




23-PPV 7-PCV 13-PCV 
1 X  X 
2 X   
3 X  X 
4 X X X 
5 X  X 
6A   X 
6B X X X 
7F X  X 
8 X   
9N X   
9V X X X 
10A X   
11A X   
12F X   
14 X X X 
15B X   
17F X   
18C X X X 
19A X  X 
19F X X X 
20 X   
22F X   
23F X X X 
33F X   
23-PPV: 23-valent polysaccharide vaccine; 7-PCV: heptavalent conjugate vaccine; 13-PCV: 13-valent conjugate vaccine 
PCV: 13-valent conjugate vaccine. Courtesy of RU Sorensen, MD. 
Table 1. Pneumococcal vaccines and antibody testing for conjugate and pure pneumococcal 
polysaccharides 
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 Vaccine 
 Conjugate (CV)* Polysaccharide (PV) 
Normal infants 2, 4, 6, 12-15 months Not given to patients this age 
7 to 11 months 3 doses Not given to patients this age 
12 to 23 months 2 doses 
Not given to patients this age 
∆ 
2 to 5 years 1 dose◊ 1 dose 
>5 years  1 dose § 
The measurement of pre-immunization immunoglobulin and serotype-specific antibody concentrations, as well as 4 -
to-6-week post immunization serotype-specific antibody concentrations are recommended. 
* Recommendations for the use of CV are based upon the recommendations of the CDC Advisory Committee (press 
release 10/22/99), FDA (HHS News release 2/17/00) and of the American Council on Immunization Practices [4]. 
 Intervals between doses of any vaccine combination should be ≥ 2 months. 
∆ One study showed excellent serological responses to 22 of the 23 serotypes in the PV vaccine in 56 12-month old 
children. [7] These results support personal observations (Sorensen RU) of good responses to PV in younger children. 
The use of PV in patients 12-24 months of age could be considered when CVs are not available. 
◊ Patients with IgG2 deficiency may require 2 doses at any age [62]. 
§ If there is no antibody response to PV, give CV; repeating PV is not effective [55]. 
Adapted from: Sorensen RU, Moore C. Peds Clin N A 2000;42:1225. 
Table 2. Pneumococcal immunization in patients with recurrent infections 
Severity of deficiency 
IgG anti-pneumococcal antibodies 
Post-immunization 
2-5 years of age ≥6 years of age 
Severe 
No protective antibody levels for 
any serotype 
No protective antibody levels 
for any serotype 
Moderate 
Protective antibody levels for <50% 
of serotypes administered 
Protective antibody levels for 
<70% of serotypes 
administered 
A protective antibody concentration is defined as ≥1.3 micrograms/mL, based on response to polysaccharide vaccine 
serotypes in patients >2 years of age. 
If a patient previously received the conjugate pneumococcal vaccine and had protective titers to those serotypes, then 
an adequate response would be expected to the age-appropriate percentage (50% or 70%) of those serotypes exclusive 
to the polysaccharide vaccine. 
%: percent of polysaccharide vaccine serotypes administered and tested. 
Adapted from Sorensen, RU, Moore, C. Peds Clin N A 2000;43:1225. 
Table 3. Classification of deficient response to pneumococcal vaccination 
3. Measurement of specific antibody responses 
Various methods for the measurement of antigen-specific antibodies include 
nephelometry, turbidimetry, chemiluminescence and enzyme-linked assay (ELISA) . 
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Although infections and immunizations elicit IgM, IgA, and IgG antibody responses, only 
IgG titers are relevant to the assessment of vaccine responses. IgG antibodies confer long-
term protection and are considered indicative of immunity. The specific IgG titer 
represents the total of all IgG subclass concentrations, since most antibody tests do not 
differentiate among Ig subclasses. 
For IgG anti-pneumococcal antibody assessment, the standard method is the third 
generation WHO ELISA, which incorporates double absorption of samples with capsular 
polysaccharide (CPS) and serotype 22F and correlates closely with OPA measurements 
[Concepcion 2001]. Multiplex technologies allow simultaneous quantitation of multiple 
serotype-specific antibodies. There has been limited validation against the established gold 
standard ELISA and assay performance in the clinical setting has not been carefully 
examined. 
Measurements of antibodies to all 23 pneumococcal serotypes in a single test, without 
differentiating specific antibodies to single serotypes, is not useful. The correlation of this 
test with the standard ELISA test is poor. For instance, the presence of a high concentration 
antibody to a single serotype may give a falsely high antibody concentration, though the 
antibody response to other serotypes may be deficient.  
Ideally, evaluation of antibody-mediated immunity includes the measurement of 
immunoglobulin and pre-immunization anti-pneumococcal antibody concentrations, with 
follow-up assessment of post immunization antibodies four to six weeks later. In practice 
today, most patients needing evaluation for recurrent infections have already received one 
or more pneumococcal vaccines and pre-immunization antibody concentrations cannot be 
measured. So, an exact immunization history becomes essential for the adequate 
interpretation of results [43].  
When there is a good initial clinical and serological response to vaccination but clinical 
infections recur after a period of time, usually 6 to 12 months, the antibody evaluation is 
repeated to rule out a rapid loss of antibody concentration down to non-protective 
concentrations.  
In most cases, evaluation of specific antibody deficiency is based on the response to 
pneumococcal polysaccharides. In some circumstances, it is also important to consider the 
response to other vaccines or infections. In patients with hypogammaglobulinemia in the 
first year of life, the response to protein antigens such as tetanus and diphtheria toxoids may 
help to predict whether the patients has transient hypogammaglobulinemia of infancy, and 
whether the low IgG concentrations will spontaneously increase into the normal range. The 
present role of the response to the conjugate Hemophilus influenzae type b vaccine has not 
been well defined.  
The measurement of anti-A and B isoagglutinins is not useful in the diagnosis of specific 
antibody deficiency. Blood groups A and B are galactosamines on red blood cells that cross-
react with galactosamines on the capsule of gut E coli bacteria. The method currently in use 
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does not differentiate between IgM and IgG responses so is not clinical useful except for in 
rare instances, such as suspected Wiskott-Aldrich syndrome that needs evaluation in the 
first year of life. A normal child should have detectable isogglutinin titers after age 6 
months.  
In patients with persistent or recurrent infections with a single pathogen, such as varicella, 
shingles, or a specific hepatitis, assessing the specific antibody response to a causative 
pathogen may be clinically relevant. However, such evaluations are usually not part of the 
evaluation for SAD. 
4. Diagnostic criteria  
The interpretation of anti-pneumococcal antibody concentration results is based on 
increased post-immunization antibody concentrations over pre-immunization 
concentrations (immune response) and on the final post-immunization antibody 
concentrations, regardless of increase from pre-immunization concentrations (antibody 
concentration). Patients who already have high baseline antibody concentrations of specific 
antibodies to a pneumococcal serotype are less likely to have a significant increase in 
antibody concentrations after immunization.  
The definition of adequate response to individual pneumococcal polysaccharides is not  
well defined. Protection against invasive disease, as assessed in clinical vaccine trials,  
may require lower antibody concentrations that protection against mucosal diseases  
like sinusitis and otitis [10]. Immunocompetence, as a reflection of the ability of producing a 
response for clinical protection against mucosal infections and pneumonia,  
has been arbitrarily defined as a post-immunization antibody concentration ≥1.3 mcg/mL. 
This antibody concentration can be used as a marker of immunocompetence, regardless  
of degree of response over pre-immunization baseline antibody concentrations [56].  
For instance, a patient with a pre-immunization titer of 0.15 mcg/mL may have a 4-fold 
increase to 0.6 mcg/ml, still significantly below the level needed to show 
immunocompetence.  
The number of individual polysaccharide responses required in the immunologic evaluation 
for a reliable assessment of the antibody response to polysaccharides has not been 
established. Response to a single serotype-specific polysaccharide does not predict the 
ability or inability to respond to most or all other serotypes. Therefore, measuring response 
of at least six different antibodies to vaccine serotypes is recommended to obtain a reliable 
estimate of the spectrum of responses of a given patient. For patients who received one or 
more doses of the conjugate pneumococcal vaccine, at least six or more non-conjugate 
vaccine serotypes (present only in polysaccharide vaccine) need to be measured. A patient 
that responds to the conjugate vaccine may still be unresponsive to pure polysaccharides, 
which is an immunologic abnormality that may be clinically relevant.  
The age of the patient significantly affects the intensity of the antibody response  
to individual serotypes and the number of serotypes inducing an adequate response [56]. 
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Normal children between two and five years of age are expected to have an  
adequate response to >50 percent of serotypes evaluated. Older patients are expected to 
respond to >70 percent of serotypes evaluated. These criteria have not been tested critically; 
however, they have allowed us to predict a clinical course and decide upon treatment 
options in over 1000 patients of all ages tested since 1995 (Sorensen et al, unpublished 
observations). 
Other factors that affect pneumococcal antibody concentrations in the evaluation of SAD 
include treatment with intravenous or subcutaneous gammaglobulin within the previous 6 
months and underlying diseases and/or treatments possibly affecting immune response. 
Examples include long-term steroid therapy, malignancy, and chemotherapy.  
In addition to immunization, responses to natural, often subclinical, infection influence the 
antibody concentrations in patients. In fact, absent protective antibodies in unimmunized 
patients above 2 years of age are unusual. However, upon vaccination, older patients who 
never developed protective antibodies to pneumococcal serotypes often have adequate 
response to most serotypes. Low antibody concentrations in an unimmunized individual do 
not define an immunodeficiency syndrome unless there is inadequate response to 
immunization.  
5. Clinical manifestations  
The clinical manifestations of patients with selective anti-polysaccharide antibody deficiency 
are similar to those of all antibody deficiency syndromes. The majority of patients have 
recurrent upper and/or lower respiratory infections such as sinusitis, otitis, bronchitis or 
pneumonia due to Streptococcus pneumoniae, Haemophilus influenzae, Branhamella catarrhalis, or 
Staphylococcus aureus.  
The sinopulmonary infections must be more frequent or severe that normally expected for 
the age group of the patient. Most of these infections require antibiotic treatment for clinical 
improvement, and an evaluation is warranted when multiple antibiotic treatments are 
needed, even when antibiotics effectively resolve each infection.  
For a common infection such as otitis media, characteristics frequently found in patients 
with SAD include: 
• Early onset of infections, as early as 3-4 months of age 
• Recurrence of infection after antibiotic treatment 
• Infectious complications such as mastoiditis 
• Association with invasive infections 
• Recurrence after ear tubes 
• Repeated ear tube placement 
• Clinical change to sinusitis after ear tubes 
Very few patients with specific antibody deficiency also present with atopic  
diseases, including atopic dermatitis and asthma, complicated by recurrent infections 
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requiring frequent antibiotic treatments for improvement. Patients with asthma and 
selective antibody deficiency may also have chronic sinusitis or other recurrent 
sinopulmonary infections. 
6. Sad phenotypes 
There are many different forms of SAD based on the immunologic and clinical phenotypes, 
the transient or permanent nature of the defect, and the maintenance or loss of antibody 
concentrations after an initial normal response.  
The classic SAD with absent or poor responses to pneumococcal polysaccharides is well 
defined and is based on the response to polysaccharides from serotypes present in PPV23. 
When patients have received one or more conjugate pneumococcal vaccines, differentiating 
antibody responses to serotypes present in the conjugate vaccines from responses to 
serotypes present only in the polysaccharide vaccines is important. In specific antibody 
deficiency, antibody response to the conjugate serotypes may be normal with poor 
responses to polysaccharide serotypes.  
The intensity of antibody responses to polysaccharides and the number of polysaccharides 
eliciting antibody responses vary considerably from one individual to another, even in the 
same age group. This variability makes it difficult to clearly define immunologic phenotypes 
of polysaccharide antibody unresponsiveness. 
The severe immunologic phenotype of SAD is the easiest phenotype to define. These 
patients have little or no antibody response and no protective antibody concentrations to 
any pneumococcal serotype evaluated . Some patients with a severe immunologic 
phenotype have protective titers to one serotype, and the titer tends to be low (1.3 to 2.0 
ug/ml) [45, 51]. 
A moderate immunologic SAD phenotype is characterized by partial antibody responses, 
with less than the expected arbitrarily defined adequate response to serotypes for their age 
group. Some of these patients can have a severe clinical phenotype despite their relatively 
mild or moderate immunological abnormality.  
Since the introduction of conjugate pneumococcal vaccines in the USA in 2000, patients with 
recurrent respiratory infections who are fully immunized with 4 doses of PCV may be 
clearly unresponsive to conjugate polysaccharides. These patients usually are able to 
develop protective antibody concentrations against protein antigens such as diphtheria and 
tetanus toxoids and to the single antigen conjugate Haempphilus influenza vaccine. The 
immunologic and clinical severity of these patients is similar to the phenotypes of patients 
unresponsive to PPV. There is a large subgroup of PCV-SAD patients that respond only to 
serotype 14, revealing that the immunologic properties of the polysaccharide in serotype 14 
is different from other penumococccal polysaccharides.  
A different clinical phenotype of SAD occurs in patients who have an initial adequate 
response to a pneumococcal vaccine, followed by a rapid loss of antibody concentrations 
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over time. This form of SAD, based on poor persistence of IgG antibodies against 
pneumococci, is usually suspected when a patient who had a significant improvement with 
decreased infections after immunization begins again to have recurrent infections, typically 
six or more months post-immunization.  
Some unimmunized patients in all age groups fail to develop protective antibody 
concentrations to any pneumococcal serotype tested. This lack of antibody response is 
unusual in individuals above two years of age who typically develop antibodies in response 
to natural infections. Most unimmunized adults have protective antibodies to at least 80 
percent of serotypes tested. The lack of pre-immunization protective antibodies does not 
define an immunodeficiency, and most of these patients have a normal response to 
immunization. Those patients that completely fail to respond to natural infection and 
immunization have a severe form of selective antibody deficiency. Responders to 
immunization cannot be differentiated from non-responders without evaluation with 
immunization and retesting after immunization. 
7. Management of SAD 
The management of SAD, including prevention and treatment of recurrent infections, can be 
classified into the following broad categories: additional immunization, antibiotic 
prophylaxis and treatment, and immune serum globulin therapy. 
8. Immunization 
Immunization beyond the suggested regular immunization schedule should be the first step 
in a newly diagnosed SAD patient. Patients who fail to respond to a complete series of PCV 
vaccinations, PCV-SAD patients, should be immunized with one dose of PPV. This vaccine 
should increase the patient's protection against bacterial polysaccharide infections, and this 
immunization allows for assessment of the patient's immunologic response to 
polysaccharides. Clinical experience shows that these patients typically have good 
immunologic response to most or all 23 PPV serotypes (Sorensen, unpublished 
observations).  
Patients with recurrent infections despite good response to PCV may benefit from 
immunization with PPV. PPV contains serotypes common to PCV and serotypes no present 
in PCV, so this vaccine may increase antibody response to PCV and nonPCV serotypes. For 
less severe mucosal infections not requiring multiple antibiotic treatments, it may be 
possible to immunize the patient first, with a subsequent complete immunological 
evaluation only if infections persist. 
After immunizing with one dose of PPV initially, repeated immunization with PPV should 
not be considered a routine therapeutic option in patients with recurrent infections that fail 
to respond to PPV. If patients do not respond to one dose of PPV-23, our experience 
suggests that these patients likely do not have an appropriate immunologic response to 
polysaccharide antigens. So, a second dose of PPV-23 generally has little benefit. An 
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exception may be re-immunization of otherwise immunologically normal patients who 
partially responded to PPV initially, with resulting titers slightly below protective levels.. 
Reimmunization of partial responders to PPV may result in protective antibody levels. 
In contrast to the ineffectiveness of repeated PPV immunization, 80 to 90 percent of patients 
with classic PPV-SAD do have a serological response to the serotypes present in the 
conjugate vaccine that can be used to overcome the unresponsiveness to pure 
polysaccharides [56]. Conjugate vaccines were developed to immunize children younger than 
2 years of age, as children below age 2 years typically demonstrate poor responses to 
polysaccharide antigens alone. Conjugation helps direct the immune response toward the 
immunogenic protein complexed to the polysaccharide antigen, thereby stimulating 
protective immune responses in those individuals. Therefore, it is not surprising that PPV-
nonresponders typically have a good serological response to PCV serotypes.  
Although most patients benefit from immunization with the conjugate vaccine by improving 
protection against common pneumococcal serotypes, none of the conjugate vaccines has all 23 
serotypes present in the polysaccharide vaccine. This clinical improvement after a PCV 
immunization is notable because recurrent respiratory infections are caused by a much larger 
variety of pathogens than just the vaccine pneumococcal serotypes.  
If there is a serological response to the conjugate vaccine without clinical improvement, then 
the PPV-SAD persists and further treatment options need to be considered. In PPV-SAD 
patients who are clinically unresponsive to immunization with additional PCV, 
reimmunizing with PPV is generally ineffective if repeated within one year of the initial 
PPV vaccine. After a period of IgG therapy, many patients respond to an additional PPV 
dose with or without clinical improvement, so a second PPV dose should be given after 
completion of 1-2 years of IgG replacement therapy. 
For patients with poor immunological memory (loss of antibody concentrations after an 
adequate initial response), immunization with a second dose of polysaccharide vaccine 
generally triggers a vigorous IgG antibody response. Further study is needed since this 
phenotype may not be attributable only to poor immunological memory. 
9. Antibiotics 
If the frequency and severity of infections persists after additional immunization, antibiotic 
prophylaxis should be considered, especially in younger patients who will likely outgrow 
their selective antibody deficiency. When an oral antibiotic is considered for prophylaxis, 
treatment doses of trimetroprim-sulfa can be very effective. Prolonged daily use of topical 
mupirocin intranasally, for several months to a year, is a safe alternative treatment plan.  
Appropriate antibiotic selection and duration for any febrile and/or purulent respiratory 
infection is important. Treatment with high doses of antibiotics for periods of at least 2 to 3 
weeks is necessary. When antibiotic use alone improves the patient’s quality of life and 
prevents infectious complications, no additional treatment is needed.  
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10. IgG replacement therapy  
IgG replacement by the intravenous or the subcutaneous route is appropriate when the 
infection history is well documented, when immunizations have been utilized, and most of 
all, when proper antibiotic prophylaxis and treatment has been optimized. Patients with any 
form of SAD need decreased infections to improve quality of life and to prevent 
complications such hearing loss, sinus damage or bronchiectasis. 
The recommended IgG dose is 400 to 600 mg/kg calculated on a monthly basis. ItgG can be 
given intravenously every four weeks or subcutaneously in divided doses one or twice 
weekly. Occasional patients require either higher doses if they have breakthrough infections 
or complications such as bronchiectasis. 
When the severity of infections warrants the use of IgG replacement treatment, patients 
should be advised that treatment will be discontinued after a period of one to two years and 
the immune response will be reevaluated four to six months after discontinuation of IgG 
replacement. Whenever possible, the discontinuation of IVIG should be scheduled for 
during the spring or summer time when the incidence of infections typically decreases. 
Four to six months after the IgG dose, a complete immunological evaluation of antibody 
mediated immunity should be performed. This evaluation includes an additional dose of 
PPV and measurement of antibodies 3 to 6 weeks after immunizations. Many children do 
not require further IgG replacement therapy, but some continue to have persistent infections 
and need continue replacement IgG therapy. These patients are likely to have additional 
immunological abnormalities that presently under evaluation. Patient management, IgG 
replacement therapy, and post treatment evaluation is best done by experts in the 
management of patients with all forms of primary immunodeficiency diseases.  
11. Prognosis  
The immunologic phenotypes of specific antibody deficiency may be transient or 
permanent. Transient forms are common in children two to five years of age. Even in 
permanent phenotypes, the natural history of specific antibody deficiency is usually benign 
with proper management of these patients.  
Reassessment of antibody-mediated immunity should always be performed after 
discontinuation of IVIG therapy and in patients with recurrent infections. In particular, 
older patients with selective antibody deficiencies with normal immunoglobulin 
concentrations should be monitored closely, as they may eventually develop common 
variable immunodeficiency. 
Further insights into the pathogenesis of this immunodeficiency by studying larger numbers 
of patients will allow further understanding of the correlation between immunologic and 
clinical phenotypes of specific antibody deficiency. Further study will result in a more 
reliable assessment of the risk for persistent immune abnormalities and recurrent 
sinopulmonary infections in subgroups of these patients. 
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